Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with histological confirmation of a solid tumor.
• Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
• Patient must be ≥ 18 years old.
• All patients must have signed and dated an informed consent form.
Locations
Other Locations
Canada
Princess Margaret Cancer Centre
RECRUITING
Toronto
Contact Information
Primary
Celeste Yu, MSc
celeste.yu@uhn.ca
416-946-4501
Backup
Elizabeth Shah
elizabeth.shah@uhn.ca
416-946-4501
Time Frame
Start Date: 2022-07-20
Estimated Completion Date: 2027-06
Participants
Target number of participants: 500
Treatments
NIP IT!
Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival/fresh tumor specimens will be collected for banking and future research purposes.
Related Therapeutic Areas
Sponsors
Leads: University Health Network, Toronto
Collaborators: Princess Margaret Hospital, Canada